◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › S › SNY

Sanofi ADR (SNY) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · DATA UPDATED 2026-11-04

Sanofi ADR (SNY) operates in the DRUG MANUFACTURERS - GENERAL industry and is headquartered in Paris, France with about 74,846 employees. Its market capitalization is roughly $109 billion. In the fiscal year ended 2025-12-31, SNY reported €46.7B in revenue and €7.8B in net income.

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and Germany. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.

Interactive charts & full statements → Open the SNY valuation workbench →

SNY Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-09-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	€51.0B	€46.7B	€44.3B	€41.6B	€40.6B	€39.2B	€37.4B	€37.6B	€35.7B	€36.2B	€34.7B	€34.9B	€32.0B	€31.3B	€36.0B	€35.1B	€34.0B	€30.7B	€28.8B	€29.2B	€29.5B
Gross Profit	€37.6B	€33.7B	€31.1B	€29.0B	€28.7B	€26.9B	€25.2B	€25.7B	€24.2B	€24.6B	€24.0B	€23.9B	€21.8B	€21.0B	€24.9B	€24.2B	€24.6B	€22.9B	€21.5B	€21.6B	€21.9B
Gross Margin %	73.7%	72.1%	70.2%	69.7%	70.7%	68.7%	67.5%	68.2%	68.0%	67.9%	69.2%	68.7%	68.0%	67.1%	69.1%	69.0%	72.4%	74.4%	74.5%	74.1%	74.3%
Operating Income (EBIT)	—	€9.6B	€7.3B	€7.0B	€10.2B	€8.1B	€14.1B	€3.1B	€4.7B	€5.8B	€6.5B	€5.6B	€6.1B	€5.0B	€6.4B	€5.9B	€6.5B	€6.4B	€4.4B	€5.9B	€5.7B
Operating Margin %	—	20.5%	16.4%	16.7%	25.1%	20.7%	37.8%	8.1%	13.1%	16.0%	18.8%	16.1%	18.9%	15.9%	17.9%	16.7%	19.2%	20.7%	15.2%	20.2%	19.4%
Net Income	€4.2B	€7.8B	€5.6B	€5.4B	€8.4B	€6.2B	€12.3B	€2.8B	€4.3B	€8.4B	€4.7B	€4.3B	€4.4B	€3.7B	€4.9B	€5.6B	€5.5B	€5.3B	€3.9B	€5.3B	€4.0B
Net Margin %	8.2%	16.7%	12.6%	13.0%	20.6%	15.9%	32.9%	7.3%	12.1%	23.2%	13.6%	12.3%	13.7%	11.9%	13.6%	16.1%	16.1%	17.1%	13.4%	18.0%	13.6%
EBITDA	—	€12.5B	€11.0B	€11.4B	€13.5B	€11.5B	€17.9B	€10.7B	€9.2B	€9.6B	€9.9B	€10.1B	€9.5B	€10.2B	€11.4B	€11.6B	€11.8B	€11.4B	€10.5B	€10.8B	€12.1B
Earnings Per Share (EPS)	€1.74	€3.20	€2.22	€2.15	€3.34	€2.48	€4.90	€2.19	€1.72	€3.35	€1.83	€1.64	€1.67	€1.40	€1.85	€2.14	€2.09	€2.01	€1.46	€1.94	€1.47
Shares Outstanding (M)	—	2,441M	2,503M	2,513M	2,504M	2,505M	2,507M	1,257M	2,510M	2,514M	2,573M	2,612M	2,632M	2,646M	2,639M	2,643M	2,611M	2,613M	2,632M	2,708M	2,718M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SNY Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-09-30	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	€15.2B	€12.3B	€11.2B	€12.2B	€13.2B	€10.7B	€10.6B	€7.6B	€14.2B
Gross Profit	€11.6B	€9.3B	€8.1B	€8.6B	€9.8B	€7.7B	€7.7B	€5.4B	€10.1B
Gross Margin %	76.2%	75.5%	72.1%	70.3%	74.1%	72.1%	72.8%	70.2%	71.2%
Operating Income (EBIT)	—	€2.4B	€2.3B	(€1.0B)	€3.6B	€1.5B	€2.2B	€573M	€3.6B
Operating Margin %	—	19.4%	20.2%	-8.5%	27.5%	13.7%	21.1%	7.5%	25.7%
Net Income	€3.0B	€343M	€1.6B	(€801M)	€2.8B	€3.9B	€1.9B	€499M	€2.8B
Net Margin %	19.8%	2.8%	14.3%	-6.6%	21.3%	36.7%	17.6%	6.5%	19.9%
EBITDA	—	€1.7B	€2.7B	€3.8B	€4.2B	€1.9B	€2.8B	€563M	€4.2B
Earnings Per Share (EPS)	€1.26	€0.14	€0.67	€-0.33	€1.14	€1.60	€0.76	€0.20	€1.12
Shares Outstanding (M)	—	2,393M	2,408M	2,441M	2,468M	2,468M	2,468M	2,507M	2,506M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SNY Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	€14.3B	€12.1B	€9.1B	€10.3B	€10.5B	€10.5B	€7.4B	€7.7B	€5.5B	€7.4B	€7.8B	€8.9B	€7.7B	€7.0B	€8.2B	€9.3B	€9.8B	€8.5B	€8.5B	€7.1B	€6.6B
Capital Expenditures (CapEx)	€4.2B	€2.0B	€3.2B	€2.9B	€2.2B	€2.0B	€2.1B	€1.8B	€2.0B	€2.0B	€2.1B	€2.8B	€1.6B	€1.4B	€1.6B	€1.8B	€1.6B	€1.8B	€1.6B	€1.6B	€1.5B
Free Cash Flow (FCF)	€10.1B	€10.1B	€5.9B	€7.4B	€8.3B	€8.5B	€5.3B	€5.9B	€3.6B	€5.4B	€5.8B	€6.1B	€6.1B	€5.6B	€6.6B	€7.5B	€8.2B	€6.7B	€6.9B	€5.5B	€5.2B
FCF Margin %	20.6%	21.7%	13.3%	17.7%	20.5%	21.6%	14.3%	15.8%	10.0%	15.0%	16.6%	17.6%	19.2%	17.8%	18.2%	21.5%	24.1%	21.9%	24.0%	18.9%	17.5%
Dividends Paid	—	€5.4B	€4.7B	€4.5B	€4.2B	€4.0B	€3.9B	€3.8B	€3.8B	€3.7B	€3.8B	€3.7B	€3.7B	€3.6B	€3.5B	€1.4B	€3.1B	€2.9B	€2.7B	€2.4B	€2.0B

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SNY Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-09-30
Cash from Operations (CFO)	€5.4B	€1.7B	€3.4B	€3.8B	€1.5B	€2.1B	€3.8B
Capital Expenditures (CapEx)	€1.5B	€0M	€1.9B	€845M	€0M	€0M	€0M
Free Cash Flow (FCF)	€3.9B	€1.7B	€1.6B	€2.9B	€1.5B	€2.1B	€3.8B
FCF Margin %	31.7%	15.0%	13.0%	22.1%	13.6%	19.7%	27.2%
Dividends Paid	€5.7B	—	—	—	—	—	—

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SNY Balance Sheet History

Balance sheet	2026-09-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	€130.3B	€126.8B	€132.8B	€126.5B	€126.7B	€120.2B	€114.4B	€112.6B	€111.4B	€99.8B	€104.7B	€102.3B	€97.4B	€96.1B	€100.4B	€100.7B	€85.3B	€80.0B	€72.0B	€69.0B	€74.3B
Cash & Cash Equivalents	€6.0B	€7.7B	€7.4B	€8.7B	€12.7B	€10.1B	€13.9B	€9.4B	€6.9B	€10.3B	€10.3B	€9.1B	€7.3B	€8.3B	€6.4B	€1.9B	€5.8B	€689M	€540M	€1.7B	€1.2B
Total Liabilities	€57.0B	€55.1B	€54.9B	€52.1B	€51.6B	€51.2B	€51.2B	€53.4B	€52.4B	€41.6B	€46.9B	€44.1B	€41.1B	€39.0B	€42.9B	€44.3B	€32.0B	€31.6B	€26.9B	€24.3B	€28.5B
Total Debt (Short + Long-Term)	€19.8B	€18.9B	€16.3B	€16.9B	€19.3B	€20.6B	€22.7B	€24.9B	€24.6B	€15.6B	€18.6B	€16.4B	€30.0B	€18.5B	€17.9B	€19.2B	€10.4B	€11.4B	€7.6B	€7.7B	€8.4B
Total Shareholders' Equity	€72.9B	€71.4B	€77.5B	€74.0B	€74.8B	€68.7B	€63.1B	€59.2B	€59.0B	€58.1B	€57.6B	€58.0B	€56.1B	€56.9B	€57.3B	€56.2B	€53.1B	€48.2B	€44.9B	€44.5B	€45.6B

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SNY viewer.

Other Companies in DRUG MANUFACTURERS - GENERAL

NVS · Novartis AG ADR — $301 billion
AZN · AstraZeneca PLC — $285 billion
NVO · Novo Nordisk A/S — $176 billion
GSK · GlaxoSmithKline PLC ADR — $98 billion
GRFS · Grifols SA ADR — $6 billion
OGN · Organon & Co — $4 billion

← SNXX All “S” companies SNYR →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.